President Trump Links Tylenol Use During Pregnancy to Autism, Prompting Medical Community Backlash
President Donald Trump has advised pregnant women to limit Tylenol use, citing a potential link to autism, a claim that has been met with strong opposition from medical experts and the pharmaceutical industry.
President Donald Trump has advised pregnant women to limit the use of Tylenol (acetaminophen), suggesting a potential link between the medication and autism spectrum disorder (ASD). Speaking alongside Health Secretary Robert F. Kennedy Jr., Trump stated that acetaminophen should only be used during pregnancy when absolutely necessary, such as in cases of extremely high fever.
The medical community has responded with skepticism and concern. The American College of Obstetricians and Gynecologists (ACOG) emphasized that there is no clear evidence proving a direct relationship between the prudent use of acetaminophen during pregnancy and fetal developmental issues. ACOG President Dr. Steven J. Fleischman described the administration's announcement as "not backed by the full body of scientific evidence" and potentially harmful to pregnant patients.
Kenvue, the manufacturer of Tylenol, also refuted the claims, stating that independent, sound science clearly shows that taking acetaminophen does not cause autism. The company warned that avoiding the drug could lead pregnant women to choose riskier alternatives.
In addition to the acetaminophen advisory, the administration announced plans to make leucovorin, a drug traditionally used in cancer treatment, available for children with autism symptoms linked to cerebral folate deficiency. This move has raised concerns among experts about the promotion of unproven treatments. Dr. Shafali Jeste, a pediatric neurologist specializing in autism, cautioned that families might invest resources into treatments without data showing effectiveness, potentially at the expense of established interventions like behavioral and speech therapies.
The Centers for Disease Control and Prevention (CDC) reports that approximately 1 in 31 eight-year-old children in the U.S. were identified with autism in 2022, up from 1 in 149 in 2000. Experts attribute this increase to broader diagnostic criteria and heightened awareness, rather than a true rise in incidence.
The administration's announcements have sparked a broader debate on the causes of autism and the role of environmental factors. Medical professionals continue to advocate for evidence-based approaches and caution against drawing conclusions without robust scientific support.